Chronos Archive seal
The Human Record

Swami Vivekananda

Case HR-NI032 · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
January 12, 1863 – July 4, 1902
Synthetic DOB
1991-01-12
Index visit
2026-02-09 at age 35
Synthetic MRN
HR-NI032-SYN

Teaching objective: Diagnose and classify diabetes in a 35-year-old South Asian man at a near-normal BMI (ADA screens Asian Americans from a BMI of 23 because South Asians develop type 2 diabetes at lower weights and younger ages): confirm with A1c and fasting glucose, test GAD antibodies and C-peptide to exclude type 1 and slowly progressive autoimmune diabetes, and record the decision. Then treat by shared decision with metformin and, once moderately increased albuminuria is confirmed, an SGLT2 inhibitor; build a mostly vegetarian, culturally fitting nutrition plan with a dietitian around his monastic diet; plan safe religious fasting with medication adjustment (IDF-DAR guidance, adapted from Ramadan to Hindu fasts); screen and protect the kidneys (UACR, eGFR, blood pressure with an ARB), eyes and lipids; treat long-standing insomnia without hypnotics; and diagnose and treat adult-onset asthma on GINA track 1, managing the steroid-induced hyperglycemia of an exacerbation. His diet, fasting and monastic practice are his to decide; the clinic adapts to them.

Historical timeline

DateEventClaims
January 12, 1863Born Narendranath Datta in Calcutta.CLM-0001
November 1881Meets Sri Ramakrishna; takes monastic vows in 1887.CLM-0002
September 1893Speaks at the World's Parliament of Religions in Chicago; teaches in the West until 1897.CLM-0003
March 1897Writes that he has diabetes; goes to Darjeeling on his physicians' advice.CLM-0005
May 1, 1897Founds the Ramakrishna Mission Association; writes of lifelong trouble falling asleep.CLM-0004, CLM-0006
March 30, 1898Leaves for Darjeeling; plague relief in Calcutta; travels north from May 11.CLM-0007
October 18, 1898Returns to Belur pallid and ill, with suffocating attacks of asthma.CLM-0008
January 26, 1899Writes that the diabetes has gone and asthma has come in its place.CLM-0009, CLM-0014
June 1899Second visit to the West, returning to the Belur Math in December 1900.CLM-0010
December 12, 1901Writes of albuminuria for three years and a bleed in the right eye; asthma, diabetes and dropsy in his last illness.CLM-0011, CLM-0012, CLM-0015
July 4, 1902Dies at the Belur Math at 39.CLM-0013, CLM-0016

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D He was born Narendranath (Narendra Nath) Datta in an affluent family in Calcutta (Kolkata) on 12 January 1863. His father, Vishwanath Datta, was a successful attorney; his mother was Bhuvaneshwari Devi.
The documented date used for the synthetic date of birth.
confirmed Swami Vivekananda supports
HISTMED Master Roster v3 context
D He met Sri Ramakrishna at Dakshineswar in November 1881 and became his disciple; in 1887 he and his brother disciples took the formal vows of sannyasa and new monastic names.
Anchors the modern social history: a Hindu monk living by monastic vows.
confirmed Swami Vivekananda supports
D He left Bombay for America on 31 May 1893 and spoke at the World's Parliament of Religions in Chicago in September 1893, which made him famous; he then spent nearly three and a half years teaching Vedanta, mostly in the eastern United States and London, and returned to India in January 1897.
Anchors the modern social history: an internationally known teacher who travels and lectures.
confirmed Swami Vivekananda supports
D On 1 May 1897, at a meeting of the monastic and lay devotees of Sri Ramakrishna in Calcutta, he founded the Ramakrishna Mission Association; in February 1898 the monastery moved to a garden house at Belur on the west bank of the Ganga, and land for the Belur Math was bought in early 1898.
Anchors the modern social history: head of a monastic order and its service mission, living at the monastery by the river near Calcutta.
confirmed Swami Vivekananda supports
Nikhilananda S. Vivekananda: A Biography. Chapter: Return to India supports
Nikhilananda S. Vivekananda: A Biography. Chapter: In Northern India supports
D In March and April 1897, soon after his return to India, he wrote that he had diabetes. On 16 March he wrote: "The work has broken me down completely, and I have got 'diabetes', an incurable disease"; on 26 March: "The result of this steady work in the West and the tremendous work of a month in India upon the Bengalee constitution is 'diabetes'. It is a hereditary foe," adding that "Eating only meat and drinking no water seems to be the only way to prolong life"; and on 7 April that he had been "attacked by 'Diabetes', a fell disease" and had gone to Darjeeling, cool and "very good for the disease," where the doctors did not want him to move about. A biography says he went to Darjeeling on the advice of physicians.
The documented diabetes, at about 34, to which the modern diagnosis is linked. He called it hereditary; no relative is named. How the diagnosis was made is not recorded (urine sugar is likely but not stated).
confirmed Vivekananda S. Letter to Sister Christine, Darjeeling, 16 March 1897 (Complete Works, vol. 9, Letters, Fifth Series, CV) supports
Vivekananda S. Letter to Mrs. Ole Bull, 26 March 1897 (Complete Works, vol. 9, Letters, Fifth Series, CVI) supports
Vivekananda S. Letter to Lala Badri Sah, Darjeeling, 7 April 1897 (Complete Works, vol. 9, Letters, Fifth Series, CIX) supports
Nikhilananda S. Vivekananda: A Biography. Chapter: Return to India supports
D On 29 May 1897, from Almora, he wrote to a physician disciple that he was taking the medicines sent to him, riding morning and evening and feeling very strong, but that "I never in my life could sleep as soon as I got into bed. I must toss for at least two hours," that he felt hot after the evening meal, that "There has not been any thirst even though the days are fearfully hot," and that he was afraid of "getting fat on a too much milk diet."
His own account of lifelong difficulty falling asleep, linked to the modern insomnia; and of thirst as a symptom he watched for.
confirmed Vivekananda S. Letter to Dr. Shashi Bhushan Ghosh, Almora, 29 May 1897 (Complete Works, vol. 5, Epistles, First Series, LXXV) supports
D In 1898 he went to Darjeeling on 30 March for the cool air, came down to Calcutta to organize relief during an outbreak of plague, and left on 11 May for Nainital, Almora and Kashmir.
History only, after the true-frame index date; it explains the long gap in the modern visits.
confirmed Nikhilananda S. Vivekananda: A Biography. Chapter: In Northern India supports
D He returned to Belur on 18 October 1898. His brother disciples saw that he was "very pallid and ill. He suffered from suffocating attacks of asthma; when he emerged from its painful fits, his face looked blue, like that of a drowning man."
History only, after the true-frame index date; the documented asthma to which the modern sick visit and asthma diagnosis are linked.
confirmed Nikhilananda S. Vivekananda: A Biography. Chapter: In Northern India supports
D On 26 January 1899 he wrote from the Belur Math: "The old diabetes has now disappeared. In its place has come what some doctors call asthma, others dyspepsia, owing to nervous prostration. However, it is a most worrying disease, giving one the sensation of suffocation - sometimes for days."
History only, after the true-frame index date.
confirmed Vivekananda S. Letter to Sister Christine, Belur Math, 26 January 1899 (Complete Works, vol. 9, Letters, Fifth Series, CXXXII) supports
D He made a second visit to the West from June 1899 and returned to the Belur Math in December 1900.
History only, after the true-frame index date.
confirmed Swami Vivekananda supports
D In 1901 he wrote that "Bengal brings the asthma now and then" and that "the terrible things - Bright's disease and diabetes - have disappeared altogether" (2 September), and later (12 December) that "the last three years I have been getting albuminuria now and then," that the kidneys were "structurally all right," that a cold always increased it, and that "a small blood vessel in the right eye" had burst; his doctors put him to bed and forbade meat.
History only, after the true-frame index date. His own reports of albuminuria from about 1898, of a diagnosis of Bright's disease, and of a bleed in the right eye.
confirmed Vivekananda S. Letter to Sister Christine, Belur Math, 2 September 1901 (Complete Works, vol. 9, Letters, Fifth Series, CCIII) supports
Vivekananda S. Letter to Sister Christine, Belur Math, 12 December 1901 (Complete Works, vol. 9, Letters, Fifth Series, CCXI) supports
D According to a biography by a monk of his order, in March 1901 he was "suffering from both asthma and diabetes"; in the last year and a half of his life "Diabetes took the form of dropsy. His feet swelled ... He could hardly close his eyes in sleep," and on a physician's strict regimen he avoided water and salt, for twenty-one days taking no water at all.
History only, after the true-frame index date. The biographer's description of his last illness; the cause of the swelling is not recorded.
probable Nikhilananda S. Vivekananda: A Biography. Chapter: Towards the End supports
D He died at the Belur Math on the night of 4 July 1902, at 39, after an hour of meditation; a brother monk recalled "a little blood in his nostrils, about his mouth, and in his eyes." The physicians gave the cause as "apoplexy or sudden failure of the heart"; the monks held that he had left his body in samadhi.
History only, stated without detail and with respect for the monks' understanding of his death.
confirmed Nikhilananda S. Vivekananda: A Biography. Chapter: Towards the End supports
Swami Vivekananda supports
R Retrospective interpretation: diabetes beginning at about 34 in a man of South Asian ancestry who called it hereditary, who lived five more years without insulin, and whose thirst and sugar came and went with diet and rest, is most consistent with type 2 diabetes; slowly progressive autoimmune diabetes cannot be excluded from the record.
Retrospective; the modern classification is synthetic.
possible Vivekananda S. Letter to Mrs. Ole Bull, 26 March 1897 (Complete Works, vol. 9, Letters, Fifth Series, CVI) supports
Vivekananda S. Letter to Sister Christine, Belur Math, 26 January 1899 (Complete Works, vol. 9, Letters, Fifth Series, CXXXII) supports
Nikhilananda S. Vivekananda: A Biography. Chapter: Towards the End context
R Retrospective interpretation: albuminuria from about 1898, a diagnosis of Bright's disease, a bleed in the eye and swelling of the feet late in his life are consistent with diabetic kidney disease, perhaps with high blood pressure, but no measurement survives and other kidney or heart disease cannot be excluded.
Retrospective; the modern albuminuria and diabetic kidney disease are synthetic.
possible Vivekananda S. Letter to Sister Christine, Belur Math, 12 December 1901 (Complete Works, vol. 9, Letters, Fifth Series, CCXI) supports
Vivekananda S. Letter to Sister Christine, Belur Math, 2 September 1901 (Complete Works, vol. 9, Letters, Fifth Series, CCIII) supports
Nikhilananda S. Vivekananda: A Biography. Chapter: Towards the End supports
R Retrospective interpretation: his sudden death, which many accounts describe as the rupture of a blood vessel in the brain, could have been a brain hemorrhage or a heart event; the physicians' "apoplexy or sudden failure of the heart" does not decide between them, and his followers understand it as samadhi.
Retrospective and disputed; not used in the modern episode.
disputed Nikhilananda S. Vivekananda: A Biography. Chapter: Towards the End supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Thirst, frequent urination day and night, tiredness and about 4 kg weight loss over two months, with a random glucose of 246 mg/dL; told by physicians a year ago that he had diabetes, never confirmed with modern tests or treated except by diet. Diabetes to be confirmed and classified (type 2, type 1 or slowly progressive autoimmune diabetes) with A1c, fasting glucose, GAD antibodies and C-peptide resolved confirmed active CLM-0005
S Type 2 diabetes: A1c 9.4 percent and fasting glucose 172 mg/dL, with symptoms; GAD65 antibodies negative and fasting C-peptide preserved (2.6 ng/mL); no ketones. BMI 24.6, in the range where ADA screens Asian Americans. Classified as type 2, not type 1 or slowly progressive autoimmune diabetes active confirmed both_with_link CLM-0005, CLM-0014
S Moderately increased albuminuria on a first sample (urine albumin-to-creatinine ratio 46 mg/g), eGFR normal; to be confirmed on two of three samples over three to six months resolved confirmed active CLM-0011, CLM-0015
S Raised blood pressure in clinic (138/86, average of two readings) without a diagnosis of hypertension; home readings to be taken resolved confirmed active
S Hypertension, stage 1: clinic 138/86, 136/86 and 134/84; home average 136/86 over seven days; with moderately increased albuminuria and diabetes active confirmed active CLM-0015
S Long-standing difficulty falling asleep: by his own account he has never been able to fall asleep on getting into bed and lies awake for two hours or more most nights; worse lately with waking to pass urine; rises before dawn for meditation active confirmed both_with_link CLM-0006
S Mixed hyperlipidemia: LDL cholesterol 132 mg/dL, triglycerides 228, HDL 36 active confirmed active
S Attacks of wheeze and breathlessness for three weeks since coming down from the mountains to the damp plains, the worst last night with a sense of suffocation: peak flow 330 L/min (56 percent of predicted), oxygen saturation 94 percent, rising to 410 L/min after bronchodilator; no fever, edema or chest pain; chest X-ray and ECG without heart failure or pneumonia. Asthma to be confirmed with spirometry resolved confirmed active CLM-0008
S Asthma, adult onset, confirmed: FEV1 2.95 L (77 percent predicted) rising 470 mL (16 percent) after bronchodilator, FEV1/FVC 0.66 rising to 0.75; FeNO 44 ppb; brought on by damp air and smoke; one moderate attack treated with prednisone active confirmed both_with_link CLM-0008, CLM-0009
S Diabetic kidney disease, CKD stage G1 A2: moderately increased albuminuria on three samples over eight months (46, 41 and 34 mg/g) with eGFR above 90 active confirmed both_with_link CLM-0011, CLM-0015

Synthetic outcome measures

GradeDateMeasureResultCoding
S 2026-02-09 Glucose [Mass/volume] in Serum or Plasma 246 mg/dL (high)
Reference Random sample; 200 mg/dL or more with symptoms suggests diabetes
http://loinc.org · 2345-7
S 2026-02-09 Sodium [Moles/volume] in Serum or Plasma 136 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 2026-02-09 Potassium [Moles/volume] in Serum or Plasma 4.3 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-02-09 Creatinine [Mass/volume] in Serum or Plasma 0.96 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-02-09 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 106 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-02-09 Hemoglobin [Mass/volume] in Blood 14.6 g/dL
Reference 13.5-17.5 g/dL
http://loinc.org · 718-7
S 2026-02-09 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 2026-03-09 Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 http://loinc.org · 44261-6
S 2026-03-09 Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 2 http://loinc.org · 70274-6
S 2026-03-09 Total score [AUDIT-C] 0 http://loinc.org · 75626-2
S 2026-10-20 Maximum expiratory gas flow Respiratory system airway by Peak flow meter 330 L/min (low)
Reference 80 percent of his predicted 590 L/min
http://loinc.org · 19935-6
S 2026-02-16 Hemoglobin A1c/Hemoglobin.total in Blood 9.4% (high)
Reference Below 5.7% is normal; 6.5% or more diabetes; his target below 7%
http://loinc.org · 4548-4
S 2026-02-16 Glucose [Mass/volume] in Serum or Plasma 172 mg/dL (high)
Reference Fasting; 126 mg/dL or more indicates diabetes
http://loinc.org · 2345-7
S 2026-02-16 Glutamate decarboxylase 65 Ab [Units/volume] in Serum by Immunoassay 1.2 [IU]/mL
Reference Below 5 IU/mL negative
http://loinc.org · 56540-8
S 2026-02-16 C peptide [Mass/volume] in Serum or Plasma 2.6 ng/mL
Reference 0.8-3.5 ng/mL
http://loinc.org · 1986-9
S 2026-02-16 Albumin/Creatinine [Mass Ratio] in Urine 46 mg/g (high)
Reference 30 to 299 moderately increased; 300 or more severely increased
http://loinc.org · 9318-7
S 2026-02-16 Cholesterol [Mass/volume] in Serum or Plasma 214 mg/dL (high)
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 2026-02-16 Cholesterol in HDL [Mass/volume] in Serum or Plasma 36 mg/dL (low)
Reference 40 mg/dL or more for men
http://loinc.org · 2085-9
S 2026-02-16 Triglyceride [Mass/volume] in Serum or Plasma 228 mg/dL (high)
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 2026-02-16 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 132 mg/dL (high)
Reference <=99 mg/dL
http://loinc.org · 13457-7
S 2026-02-16 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 38 U/L
Reference 7-55 U/L
http://loinc.org · 1742-6
S 2026-02-16 Thyrotropin [Units/volume] in Serum or Plasma 1.8 mIU/L
Reference 0.4-4 mIU/L
http://loinc.org · 3016-3
S 2026-02-16 Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 312 pg/mL
Reference 232-1245 pg/mL
http://loinc.org · 2132-9
S 2026-03-23 Potassium [Moles/volume] in Serum or Plasma 4.6 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-03-23 Creatinine [Mass/volume] in Serum or Plasma 1 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-03-23 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 101 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-03-23 Albumin/Creatinine [Mass Ratio] in Urine 41 mg/g (high)
Reference 30 to 299 moderately increased; 300 or more severely increased
http://loinc.org · 9318-7
S 2026-10-27 Hemoglobin A1c/Hemoglobin.total in Blood 6.9% (high)
Reference Below 5.7% is normal; 6.5% or more diabetes; his target below 7%
http://loinc.org · 4548-4
S 2026-10-27 Glucose [Mass/volume] in Serum or Plasma 124 mg/dL (high)
Reference Fasting; 126 mg/dL or more indicates diabetes
http://loinc.org · 2345-7
S 2026-10-27 Albumin/Creatinine [Mass Ratio] in Urine 34 mg/g (high)
Reference 30 to 299 moderately increased; 300 or more severely increased
http://loinc.org · 9318-7
S 2026-10-27 Potassium [Moles/volume] in Serum or Plasma 4.5 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 2026-10-27 Creatinine [Mass/volume] in Serum or Plasma 0.98 mg/dL
Reference 0.74-1.35 mg/dL
http://loinc.org · 2160-0
S 2026-10-27 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 103 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 2026-10-27 Cholesterol [Mass/volume] in Serum or Plasma 152 mg/dL
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 2026-10-27 Cholesterol in HDL [Mass/volume] in Serum or Plasma 39 mg/dL (low)
Reference 40 mg/dL or more for men
http://loinc.org · 2085-9
S 2026-10-27 Triglyceride [Mass/volume] in Serum or Plasma 146 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 2026-10-27 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 84 mg/dL
Reference <=99 mg/dL
http://loinc.org · 13457-7
S 2026-10-27 FEV1 --pre bronchodilation 2.95 L (low)
Reference Lower limit of normal; predicted 3.85 L; lower limit of normal 3.10 L (GLI Global race-neutral equations)
http://loinc.org · 20157-4
S 2026-10-27 FEV1 --post bronchodilation 3.42 L
Reference Lower limit of normal; predicted 3.85 L; lower limit of normal 3.10 L (GLI Global race-neutral equations)
http://loinc.org · 20155-8
S 2026-10-27 FEV1 measured/predicted 77% (low)
Reference GLI Global race-neutral equations
http://loinc.org · 20152-5
S 2026-10-27 FEV1/FVC 0.66 (low)
Reference Lower limit of normal for his age (GLI Global)
http://loinc.org · 19926-5
S 2026-10-27 FEV1/FVC --post bronchodilation 0.75
Reference Lower limit of normal for his age (GLI Global)
http://loinc.org · 69970-2
S 2026-10-27 Fractional concentration of exhaled nitric oxide 44 [ppb] (high)
Reference Above 50 ppb high; 25 to 50 intermediate (ATS)
http://loinc.org · 96269-6
S 2026-10-27 Total score [ACT] 15 http://loinc.org · 82668-5
S 2026-10-27 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 http://loinc.org · 55758-7

Synthetic vital signs

DateMeasureResultLOINCGrade
2026-02-09Body height172 cm8302-2S
2026-02-09Body weight73 kg29463-7S
2026-02-09Body mass index (BMI) [Ratio]24.7 kg/m239156-5S
2026-02-09Systolic blood pressure138 mm[Hg]8480-6S
2026-02-09Diastolic blood pressure86 mm[Hg]8462-4S
2026-02-09Heart rate84 /min8867-4S
2026-02-09Respiratory rate16 /min9279-1S
2026-02-09Body temperature36.8 Cel8310-5S
2026-02-09Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-02-16Body height172 cm8302-2S
2026-02-16Body weight72.8 kg29463-7S
2026-02-16Body mass index (BMI) [Ratio]24.6 kg/m239156-5S
2026-02-16Systolic blood pressure136 mm[Hg]8480-6S
2026-02-16Diastolic blood pressure86 mm[Hg]8462-4S
2026-02-16Heart rate80 /min8867-4S
2026-02-16Respiratory rate16 /min9279-1S
2026-02-16Body temperature36.7 Cel8310-5S
2026-02-16Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-03-09Body height172 cm8302-2S
2026-03-09Body weight73.4 kg29463-7S
2026-03-09Body mass index (BMI) [Ratio]24.8 kg/m239156-5S
2026-03-09Systolic blood pressure134 mm[Hg]8480-6S
2026-03-09Diastolic blood pressure84 mm[Hg]8462-4S
2026-03-09Heart rate76 /min8867-4S
2026-03-09Respiratory rate14 /min9279-1S
2026-03-09Body temperature36.7 Cel8310-5S
2026-03-09Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-03-23Body height172 cm8302-2S
2026-03-23Body weight73.8 kg29463-7S
2026-03-23Body mass index (BMI) [Ratio]24.9 kg/m239156-5S
2026-03-23Systolic blood pressure128 mm[Hg]8480-6S
2026-03-23Diastolic blood pressure80 mm[Hg]8462-4S
2026-03-23Heart rate74 /min8867-4S
2026-03-23Respiratory rate14 /min9279-1S
2026-03-23Body temperature36.6 Cel8310-5S
2026-03-23Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
2026-10-20Body height172 cm8302-2S
2026-10-20Body weight74.6 kg29463-7S
2026-10-20Body mass index (BMI) [Ratio]25.2 kg/m239156-5S
2026-10-20Systolic blood pressure132 mm[Hg]8480-6S
2026-10-20Diastolic blood pressure82 mm[Hg]8462-4S
2026-10-20Heart rate108 /min8867-4S
2026-10-20Respiratory rate24 /min9279-1S
2026-10-20Body temperature36.9 Cel8310-5S
2026-10-20Oxygen saturation in Arterial blood by Pulse oximetry94 %59408-5S
2026-10-27Body height172 cm8302-2S
2026-10-27Body weight74.8 kg29463-7S
2026-10-27Body mass index (BMI) [Ratio]25.3 kg/m239156-5S
2026-10-27Systolic blood pressure126 mm[Hg]8480-6S
2026-10-27Diastolic blood pressure78 mm[Hg]8462-4S
2026-10-27Heart rate82 /min8867-4S
2026-10-27Respiratory rate16 /min9279-1S
2026-10-27Body temperature36.6 Cel8310-5S
2026-10-27Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
Diabetes confirmed and classified within a week2026-02-16completedType 2 diabetes confirmed by A1c 9.4 percent and fasting glucose 172 mg/dL; GAD65 antibodies negative and C-peptide preserved
A1c below 7 percent without hypoglycemia, in a way that fits his diet and fasts2026-10-27completedA1c 6.9 percent on metformin; no hypoglycemia; fasts kept safely
Blood pressure below 130/802026-03-23completedHome 128/80 and clinic 128/80 two weeks after starting losartan
Albuminuria reduced and kidney function preserved2027-01-26activeUrine albumin-to-creatinine ratio down from 46 to 34 mg/g; eGFR 103; empagliflozin started
Falling asleep within 30 minutes on most nights2026-12-08activeAbout 45 minutes after four of six sessions

Interventions

InterventionStatusGuideline
Endocrinology consultation in one week, the same day as fasting blood tests, to confirm and classify diabetes (A1c, fasting glucose, GAD antibodies, C-peptide), and advise on treatment that fits his diet, his religious fasts and his travelcompletedGL-ADA-DX-2026, GL-ADA-PHARM-2026, GL-CMID-2026
Diagnostic tests in one week, fasting: A1c, fasting plasma glucose, GAD65 antibodies, C-peptide, urine albumin-to-creatinine ratio, lipid panel, ALT, TSH and vitamin B12; urine ketones negative today; drink water freely while thirsty and avoid waterless fasts until the results are known; return the same day if vomiting, abdominal pain or drowsinesscompletedGL-ADA-DX-2026, GL-ADA-PHARM-2026, GL-CMID-2026, GL-ADA-COMORB-2026
Home blood pressure readings twice daily for a week with a validated upper-arm cuff, because clinic readings are raisedcompletedGL-ADA-CVD-2026, GL-CMID-2026
Insomnia: sleep diary for two weeks, screening for sleep apnea, and cognitive behavioral therapy for insomnia adapted to his pre-dawn meditation; no sleeping tablets, by his preference; nocturia to be reviewed once glucose is treatedcompletedGL-ACP-INS-2016, GL-AASM-INS-2021
Metformin extended-release with the evening meal, titrated to 2000 mg, chosen by shared decision over early combination therapy or an injected GLP-1 receptor agonist; home glucose meter; diabetes education and medical nutrition therapy for a mostly vegetarian plan built on his monastery meals, his choices and his fasts; sulfonylureas avoided because of fastingcompletedGL-ADA-PHARM-2026, GL-ADA-BEH-2026, GL-SA-PLANT-2022, GL-CMID-2026
Religious fasting plan adapted from IDF-DAR risk stratification: fasts with fruit, milk and water allowed; waterless fasts only once glucose is steady, with hydration; metformin with the meal that ends the fast; glucose checks at midday and before breaking the fast; break the fast below 70 or above 300 mg/dL or when unwellcompletedGL-IDF-DAR-2021, GL-ADA-BEH-2026
Vaccines for an adult with diabetes: influenza and COVID-19 each season, PCV20 once, hepatitis B (two doses) and TdapcompletedGL-CDC-IMZ-MC-2026, GL-CDC-IMZ-2026
Hypertension with albuminuria: losartan 25 mg daily (an ARB rather than an ACE inhibitor, to avoid cough), less salt, home readings, potassium and creatinine two weeks after startingcompletedGL-ADA-CVD-2026, GL-ADA-CKD-2026, GL-CMID-2026
Cardiovascular prevention: atorvastatin 10 mg daily at 35 with diabetes, South Asian ancestry, albuminuria and hypertension, by his choice; lipid panel six to twelve weeks after startingcompletedGL-ADA-CVD-2026, GL-SOUTHASIAN-2013, GL-CMID-2026
Travel plan for months away: medicine and test-strip supply, sick-day rules (hold metformin and losartan when vomiting, with diarrhea or unable to drink), monthly messages with readings, and A1c, urine albumin and lipids at three months wherever he iscompletedGL-ADA-PHARM-2026, GL-CMID-2026
Asthma attack in a man with diabetes: prednisone 40 mg for five days with glucose checks before breakfast and the evening meal and a call for readings above 300 mg/dL; as-needed budesonide-formoterol until spirometry; review within a weekcompletedGL-GINA-2025, GL-ADA-GLY-2026
Diabetic kidney disease G1 A2: empagliflozin 10 mg each morning, skipped on waterless fast days and stopped with metformin when unable to eat or drink; losartan continued; potassium, creatinine and urine albumin in three months, then every six monthscompletedGL-ADA-CKD-2026, GL-KDIGO-CKD-2024, GL-IDF-DAR-2021
Asthma on GINA track 1, step 3: budesonide-formoterol one inhalation twice daily and as needed with a spacer, a written action plan, a smoke-free room, review in four to six weeks and spirometry in three monthscompletedGL-GINA-2025, GL-NAEPP-2020, GL-CMID-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 Swami Vivekananda Belur Math (Ramakrishna Math and Ramakrishna Mission) biography
SRC-0002 Nikhilananda S. Vivekananda: A Biography. Chapter: Return to India Ramakrishna-Vivekananda Center of New York (via ramakrishnavivekananda.info) biography
SRC-0003 Nikhilananda S. Vivekananda: A Biography. Chapter: In Northern India Ramakrishna-Vivekananda Center of New York (via ramakrishnavivekananda.info) biography
SRC-0004 Nikhilananda S. Vivekananda: A Biography. Chapter: Towards the End Ramakrishna-Vivekananda Center of New York (via ramakrishnavivekananda.info) biography
SRC-0005 Vivekananda S. Letter to Sister Christine, Darjeeling, 16 March 1897 (Complete Works, vol. 9, Letters, Fifth Series, CV) Advaita Ashrama (Complete Works), via Wikisource primary
SRC-0006 Vivekananda S. Letter to Mrs. Ole Bull, 26 March 1897 (Complete Works, vol. 9, Letters, Fifth Series, CVI) Advaita Ashrama (Complete Works), via Wikisource primary
SRC-0007 Vivekananda S. Letter to Lala Badri Sah, Darjeeling, 7 April 1897 (Complete Works, vol. 9, Letters, Fifth Series, CIX) Advaita Ashrama (Complete Works), via Wikisource primary
SRC-0008 Vivekananda S. Letter to Dr. Shashi Bhushan Ghosh, Almora, 29 May 1897 (Complete Works, vol. 5, Epistles, First Series, LXXV) Advaita Ashrama (Complete Works), via Wikisource primary
SRC-0009 Vivekananda S. Letter to Sister Christine, Belur Math, 26 January 1899 (Complete Works, vol. 9, Letters, Fifth Series, CXXXII) Advaita Ashrama (Complete Works), via Wikisource primary
SRC-0010 Vivekananda S. Letter to Sister Christine, Belur Math, 2 September 1901 (Complete Works, vol. 9, Letters, Fifth Series, CCIII) Advaita Ashrama (Complete Works), via Wikisource primary
SRC-0011 Vivekananda S. Letter to Sister Christine, Belur Math, 12 December 1901 (Complete Works, vol. 9, Letters, Fifth Series, CCXI) Advaita Ashrama (Complete Works), via Wikisource primary
SRC-0012 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the classification as type 2 diabetes (GAD antibodies negative, C-peptide preserved, no ketosis), metformin alone at diagnosis with an A1c of 9.4 percent by his choice, the delay of the SGLT2 inhibitor until albuminuria was confirmed, losartan for stage 1 hypertension with albuminuria, the statin at 35, the adapted IDF-DAR fasting plan, the missed three-month A1c and post-statin lipid checks while he travelled, the prednisone course in a man with diabetes, and asthma on GINA track 1.
provenance reviewnot_startedHe died in 1902; the recent-death rule does not apply. Claims rest on the Belur Math biography, three chapters of Swami Nikhilananda's biography, and seven of his own letters in the Complete Works (via Wikisource). His diabetes (1897), insomnia (1897), asthma (1898 to 1901) and albuminuria are documented in his own words; the classification of his diabetes, his kidney disease and the cause of his death are R.
safe messaging reviewnot_startedNo mental health or substance claim is made; mood screens are synthetic and negative. His monastic life, diet and fasts are described with respect and left to his choice. His death is recorded once, with the physicians' and the monks' understandings side by side. No disciple, brother monk or other real person is named or given a role in the modern episode.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.